Information Provided By: 
Fly News Breaks for June 23, 2016
PSDV
Jun 23, 2016 | 08:39 EDT
FBR Capital analyst Vernon Bernardino thinks pSivida is on track to announce the 12-month data from the first Medidur Phase III trial, which he expects to be a significant catalyst, in July and that an IND filing for a Durasert osteoarthritis product by the company's partner is on track to be announced in the next few weeks. Given the company's upcoming catalysts, its potential to turn positive on cash flow in the near-term and its attractive potential as an acquisition target, the firm reiterates its Outperform rating on pSivida.
News For PSDV From the Last 2 Days
There are no results for your query PSDV
